Citius Oncology expands Lymphir distribution to Turkey and Middle East

Citius Oncology (CTOR)has entered into an exclusive distribution agreement with Er-Kim, a pharmaceutical distributor based in Turkey, for Lymphir, a novel IL-2 receptor-directed cytotoxin, approved by the FDA for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. Er-Kim will be the exclusive distributor of Lymphir in Turkey and key Gulf Cooperation Council countries, including Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the United Arab Emirates. The agreement expands Citius Oncology’s international strategy to a total of 19 markets outside the U.S. Er-Kim will be responsible for sales, marketing and reimbursement activities, under applicable laws, in each territory. Citius Oncology will supply finished product and support Er-Kim’s efforts as part of the agreement.